Together, their initial public offerings raised about $1.5 billion, including exercises of underwriters’ options to purchase additional shares of stock. Seaport has several roles open, including clinical trial manager; senior scientist, bioanalytical science; and director, clinical quality assurance. Odyssey has several roles open, including clinical trial manager II, computational biologist and senior clinical data manager. A NextGen Class of 2022 winner, Eikon launched in 2021 and raised $381 million this year with its upsized initial public offering. The NextGen Class of 2021 winner’s initial programs focus on addressing key drivers of atherosclerotic cardiovascular disease (ASCVD).